Castle Biosciences Licenses IP for Thymoma Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Castle Biosciences said yesterday that it has licensed exclusive worldwide rights to intellectual property covering a gene expression profiling test for thymoma, rare tumors derived from the epithelial cells of the thymus gland.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.